Genmab A/S (NASDAQ:GMAB) Releases Earnings Results

Genmab A/S (NASDAQ:GMAB) released its quarterly earnings data on Tuesday. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.41), Zacks reports. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.

Here are the key takeaways from Genmab A/S’s conference call:

• Genmab reported 2025 revenue of $3.7 billion (up 19%) and expanded operating profit to $1.26 billion, while guiding 2026 revenue growth around the midpoint of 14% and targeting gross leverage below 3x by end-2027.
• Commercial momentum accelerated: proprietary medicines totaled $632 million (up 54%), with Epkinly at $468 million (+67%) and Tivdak $164 million (+26%), and Epkinly now approved in >65 countries as Genmab expands direct commercialization in Europe, Japan and the U.S.
• The Merus acquisition added petosemtamab, giving Genmab three late‑stage programs (Epkinly, Rina‑S, petosemtamab) with five breakthrough designations that management says have multi‑billion dollar potential.
• The EPCORE DLBCL‑1 Phase III of Epkinly showed a PFS benefit but missed statistical significance for overall survival, and Genmab will discuss next steps with regulators while asserting other Phase III trials remain viable as confirmatory evidence.
• 2026 is framed as a catalyst year with up to six potentially registrational readouts (including frontline and second‑line Epkinly combos, a Rina‑S readout in PROC, and one or both petosemtamab Phase IIIs), which could set the stage for multiple 2027 launches.

Genmab A/S Price Performance

NASDAQ GMAB traded down $0.73 on Wednesday, hitting $29.27. 1,721,612 shares of the stock were exchanged, compared to its average volume of 1,796,661. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $35.43. The company has a market capitalization of $18.80 billion, a price-to-earnings ratio of 12.46, a P/E/G ratio of 17.63 and a beta of 0.90. The company’s 50-day moving average price is $32.30 and its two-hundred day moving average price is $29.88.

Key Headlines Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Company announced a targeted share buy‑back to cover restricted stock unit obligations (up to 342,130 shares, ~725 million DKK), offering direct buy‑side support for the stock. Genmab Announces Initiation of Share Buy‑Back Program
• Positive Sentiment: Multiple broker actions add upside sentiment: HC Wainwright raised its price target to $40 (buy), Jefferies initiated coverage with a $41.50 PT (buy), and Morgan Stanley began coverage — all signal analyst conviction and higher consensus valuation. HC Wainwright price target raise / analyst coverage
• Neutral Sentiment: Genmab published its 2025 Annual Report and filed Form 20‑F with the U.S. SEC — provides full-year detail and the outlook for 2026 for investors doing fundamental due diligence. Genmab Files Annual Report with the U.S. SEC
• Neutral Sentiment: Company summoned its Annual General Meeting for March 19, 2026 (standard corporate governance item; board candidate list attached). Notice to Convene the Annual General Meeting of Genmab A/S
• Negative Sentiment: Q4 results: EPS missed expectations (~$0.05 reported vs. ~$0.46 consensus) even though revenue (~$1.06B) was in line; the EPS miss is the main near‑term negative catalyst pressuring the stock. Investors should review the earnings slides and call for management commentary on margin and one‑offs. Genmab Q4 2025 earnings / transcript
• Negative Sentiment: FY‑2026 guidance entry in the feed is garbled; unclear guidance communication can increase investor uncertainty until clarified in filings/quarterly materials — monitor the company’s official 2026 guidance disclosure and investor slides. Q4 results slide deck

Institutional Trading of Genmab A/S

Institutional investors have recently bought and sold shares of the company. Paradigm Biocapital Advisors LP bought a new stake in Genmab A/S during the third quarter valued at about $117,063,000. Orbis Allan Gray Ltd boosted its stake in Genmab A/S by 30.2% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after purchasing an additional 3,340,456 shares during the period. Renaissance Technologies LLC boosted its stake in Genmab A/S by 23.8% during the 4th quarter. Renaissance Technologies LLC now owns 3,492,850 shares of the company’s stock valued at $107,580,000 after purchasing an additional 671,307 shares during the period. Alyeska Investment Group L.P. acquired a new stake in Genmab A/S in the 4th quarter valued at approximately $15,605,000. Finally, Deep Track Capital LP bought a new position in Genmab A/S in the 3rd quarter worth approximately $14,760,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on GMAB shares. Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Morgan Stanley initiated coverage on shares of Genmab A/S in a report on Monday. They issued an “equal weight” rating and a $34.00 price objective for the company. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Finally, Jefferies Financial Group assumed coverage on Genmab A/S in a research note on Tuesday. They set a “buy” rating and a $41.50 price target for the company. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and a consensus target price of $41.30.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.